<qa>  What is the name of the WOMEN WITH LATENT TUBERCULOSISEVALUATING THE PHARMACOKINETICS, TOLERABILITY, AND SAFETY OF ONCE-WEEKLY RIFAPENTINE AND ISONIAZID IN HIV-1-INFECTED AND HIV-1-UNINFECTED PREGNANT AND POSTPARTUM WOMEN WITH LATENT TUBERCULOSIS INFECTION: 